JP2024546436A5 - - Google Patents

Info

Publication number
JP2024546436A5
JP2024546436A5 JP2024527763A JP2024527763A JP2024546436A5 JP 2024546436 A5 JP2024546436 A5 JP 2024546436A5 JP 2024527763 A JP2024527763 A JP 2024527763A JP 2024527763 A JP2024527763 A JP 2024527763A JP 2024546436 A5 JP2024546436 A5 JP 2024546436A5
Authority
JP
Japan
Prior art keywords
complex according
oligonucleotide
tfr1
optionally
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024527763A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546436A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/079604 external-priority patent/WO2023086864A1/en
Publication of JP2024546436A publication Critical patent/JP2024546436A/ja
Publication of JP2024546436A5 publication Critical patent/JP2024546436A5/ja
Pending legal-status Critical Current

Links

JP2024527763A 2021-11-12 2022-11-10 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用 Pending JP2024546436A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163278993P 2021-11-12 2021-11-12
US202163278882P 2021-11-12 2021-11-12
US63/278,882 2021-11-12
US63/278,993 2021-11-12
US202263312633P 2022-02-22 2022-02-22
US202263312617P 2022-02-22 2022-02-22
US63/312,633 2022-02-22
US63/312,617 2022-02-22
PCT/US2022/079604 WO2023086864A1 (en) 2021-11-12 2022-11-10 Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy

Publications (2)

Publication Number Publication Date
JP2024546436A JP2024546436A (ja) 2024-12-24
JP2024546436A5 true JP2024546436A5 (cg-RX-API-DMAC7.html) 2025-11-18

Family

ID=86336621

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024527763A Pending JP2024546436A (ja) 2021-11-12 2022-11-10 顔面肩甲上腕筋ジストロフィーを処置するための筋標的化複合体およびそれらの使用

Country Status (7)

Country Link
US (1) US20250025570A1 (cg-RX-API-DMAC7.html)
EP (1) EP4429711A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024546436A (cg-RX-API-DMAC7.html)
KR (1) KR20240099448A (cg-RX-API-DMAC7.html)
CA (1) CA3234136A1 (cg-RX-API-DMAC7.html)
IL (1) IL312170A (cg-RX-API-DMAC7.html)
WO (1) WO2023086864A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11168141B2 (en) 2018-08-02 2021-11-09 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US12370264B1 (en) 2018-08-02 2025-07-29 Dyne Therapeutics, Inc. Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject
WO2020028832A1 (en) 2018-08-02 2020-02-06 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11911484B2 (en) 2018-08-02 2024-02-27 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
EP3830259A4 (en) 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
US12018087B2 (en) 2018-08-02 2024-06-25 Dyne Therapeutics, Inc. Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject
US12097263B2 (en) 2018-08-02 2024-09-24 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy
WO2021154477A1 (en) 2020-01-31 2021-08-05 Dyne Therapeutics, Inc. Anti-transferrin receptor (tfr) antibody and uses thereof
US11771776B2 (en) 2021-07-09 2023-10-03 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating dystrophinopathies
US11969475B2 (en) 2021-07-09 2024-04-30 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy
US11638761B2 (en) 2021-07-09 2023-05-02 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy
WO2023283623A1 (en) 2021-07-09 2023-01-12 Dyne Therapeutics, Inc. Muscle targeting complexes and formulations for treating dystrophinopathies
IL316143A (en) 2022-04-15 2024-12-01 Dyne Therapeutics Inc Muscle targeting complexes and formulations for the treatment of myotonic dystrophy
KR20260044219A (ko) 2023-07-21 2026-04-01 매로우 테라퓨틱스, 인크. 조혈 세포 표적화 접합체 및 관련 방법
WO2025259503A1 (en) * 2024-06-12 2025-12-18 Dyne Therapeutics, Inc. Biomarkers for facioscapulohumeral muscular dystrophy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2606152B2 (en) * 2010-08-18 2025-03-12 Fred Hutchinson Cancer Center Methods for determining the presence or risk of developing facioscapulohumeral dystrophy (fshd)
EP3830259A4 (en) * 2018-08-02 2022-05-04 Dyne Therapeutics, Inc. MUSCLE TARGETED COMPLEXES AND THEIR USES IN THE TREATMENT OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY
EP4087653A4 (en) * 2020-01-10 2024-06-19 Dyne Therapeutics, Inc. Muscle targeting complexes and uses thereof for treating myotonic dystrophy

Similar Documents

Publication Publication Date Title
JP2023535444A5 (cg-RX-API-DMAC7.html)
IL312170A (en) Muscle targeting complexes for treating facioscapulohumeral muscular dystrophy
JP2024525614A5 (cg-RX-API-DMAC7.html)
JP2024501872A5 (cg-RX-API-DMAC7.html)
JP2021533197A5 (cg-RX-API-DMAC7.html)
JP2024524222A5 (cg-RX-API-DMAC7.html)
JP2021532832A5 (cg-RX-API-DMAC7.html)
JP2023535078A5 (cg-RX-API-DMAC7.html)
JP2024503609A5 (cg-RX-API-DMAC7.html)
JP2021533200A5 (cg-RX-API-DMAC7.html)
Nishikura et al. Substrate specificity of the dsRNA unwinding/modifying activity.
JP2693643B2 (ja) キラルリン結合を有するオリゴヌクレオチド
JP2021533199A5 (cg-RX-API-DMAC7.html)
CN100393209C (zh) 用于端粒酶抑制的改性寡核苷酸
JP2023512441A5 (cg-RX-API-DMAC7.html)
JP2023512442A5 (cg-RX-API-DMAC7.html)
JP3330595B2 (ja) ウィルス(hiv)増殖抑制
IL309910A (en) Muscle targeting complexes and their uses for the treatment of myotonic dystrophy
JP2007529224A5 (cg-RX-API-DMAC7.html)
KR101605932B1 (ko) Hsf1-관련 질환을 치료하기 위한 유기 조성물
JP2023509793A5 (cg-RX-API-DMAC7.html)
JP2025512468A5 (cg-RX-API-DMAC7.html)
EP3083962B1 (en) Double-stranded polyc:poly(g/i) rna for immunostimulation and cancer treatment
AU2013306006A1 (en) Polynucleotides having bioreversible groups
JP2008220366A (ja) 修飾型pna/rna複合体